[go: up one dir, main page]

FI906307A0 - Process for the preparation of therapeutically active pyrimidine derivatives - Google Patents

Process for the preparation of therapeutically active pyrimidine derivatives

Info

Publication number
FI906307A0
FI906307A0 FI906307A FI906307A FI906307A0 FI 906307 A0 FI906307 A0 FI 906307A0 FI 906307 A FI906307 A FI 906307A FI 906307 A FI906307 A FI 906307A FI 906307 A0 FI906307 A0 FI 906307A0
Authority
FI
Finland
Prior art keywords
alkyl
cycloalkyl
alkenyl
carbon atoms
group
Prior art date
Application number
FI906307A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI95377B (en
FI95377C (en
Inventor
Rodney Brian Hargreaves
Paul William Marshall
Bernard Joseph Mcloughlin
Stuart Dennett Mills
Original Assignee
Ici Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898909054A external-priority patent/GB8909054D0/en
Priority claimed from GB898910548A external-priority patent/GB8910548D0/en
Application filed by Ici Plc filed Critical Ici Plc
Publication of FI906307A0 publication Critical patent/FI906307A0/en
Publication of FI95377B publication Critical patent/FI95377B/en
Application granted granted Critical
Publication of FI95377C publication Critical patent/FI95377C/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

This invention concerns novel aminopyrimidinium salts of the formula I: <IMAGE> in which R1 is alkyl, alkenyl, cycloalkyl, phenyl, phenylalkyl or cycloalkyl-alkyl; one of R2 and R6 is a basic group selected from amino, alkylamino, dialkylamino of up to eight carbon atoms, pyrrolidino, piperidino and morpholino; and the other of R2 and R6 is hydrogen, alkyl, alkenyl, alkoxyalkyl, phenyl, phenylalkyl, cycloalkyl or cycloalkyl-alkyl; or both of R2 and R6 are basic groups as mentioned above; and R5 is hydrogen, (1-4C)alkyl or (3-6C)alkenyl; or R2 is a basic group as mentioned above, and R5 and R6 together form alkylene or, together with the appendant carbon atoms of the pyrimidine ring, complete a benzene ring; R4 is hydrogen, alkyl, cycloalkyl-alkyl, alkenyl, alkynyl or phenylalkyl; or R4 is an optionally substitutued alkylene or alkenylene linked to the nitrogen atom of the group Q.A.N-, either of which linking groups may thereby completing a ring including two adjacent carbon atoms of Q, the carbon atoms of A and the adjacent nitrogen atom of the group -A.N-; A is a direct bond to the the group -N(R4)- or is alkylene or oxyalkylene; Q is a pyridyl, furyl, thienyl or phenyl moiety; and Y is a physiologically acceptable anion; but excluding a number of compounds specified hereinafter. The invention also includes certain closely related anhydro-base derivatives which, like the formula I compounds, possess beneficial effects on the cardiovascular system (and in particular beneficial effects modulated via the sino-atrial node). Also included are pharmaceutical compositions containing the formula I compound (or a related anhydro-base) as active ingredient, and processes for the manufacture of the various novel compounds.
FI906307A 1989-04-21 1990-12-20 Process for the preparation of therapeutically active pyrimidine derivatives FI95377C (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB898909054A GB8909054D0 (en) 1989-04-21 1989-04-21 Amino heterocycles
GB8909054 1989-04-21
GB898910548A GB8910548D0 (en) 1989-05-08 1989-05-08 Heterocyclic compounds
GB8910548 1989-05-08
PCT/GB1990/000595 WO1990012790A1 (en) 1989-04-21 1990-04-19 Pyrimidine derivatives
GB9000595 1990-04-19

Publications (3)

Publication Number Publication Date
FI906307A0 true FI906307A0 (en) 1990-12-20
FI95377B FI95377B (en) 1995-10-13
FI95377C FI95377C (en) 1996-01-25

Family

ID=26295250

Family Applications (1)

Application Number Title Priority Date Filing Date
FI906307A FI95377C (en) 1989-04-21 1990-12-20 Process for the preparation of therapeutically active pyrimidine derivatives

Country Status (29)

Country Link
US (1) US5223505A (en)
EP (1) EP0422178B1 (en)
JP (1) JP2528218B2 (en)
KR (1) KR920700203A (en)
CN (1) CN1024793C (en)
AT (1) ATE112561T1 (en)
AU (1) AU635260B2 (en)
BG (1) BG93508A (en)
CA (1) CA2014457C (en)
DE (1) DE69013112T2 (en)
DK (1) DK0422178T3 (en)
ES (1) ES2064727T3 (en)
FI (1) FI95377C (en)
GB (1) GB2230527B (en)
GR (1) GR1000371B (en)
HR (1) HRP930793A2 (en)
HU (1) HU209586B (en)
IE (1) IE63502B1 (en)
IL (1) IL94062A (en)
MW (1) MW9090A1 (en)
MY (1) MY105637A (en)
NO (1) NO177054C (en)
NZ (1) NZ233292A (en)
PL (2) PL165917B1 (en)
PT (1) PT93823B (en)
RU (1) RU2108329C1 (en)
SI (1) SI9010799A (en)
WO (1) WO1990012790A1 (en)
YU (1) YU79990A (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9012592D0 (en) * 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
GB9022644D0 (en) * 1990-10-18 1990-11-28 Ici Plc Heterocyclic compounds
US5958934A (en) * 1996-05-23 1999-09-28 Syntex (U.S.A.) Inc. Aryl pyrimidine derivatives and uses thereof
TW440563B (en) * 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
US5952331A (en) * 1996-05-23 1999-09-14 Syntex (Usa) Inc. Aryl pyrimidine derivatives
IL137922A0 (en) 1998-02-17 2001-10-31 Tularik Inc Anti-viral pyrimidine derivatives
DE69943247D1 (en) 1998-03-27 2011-04-14 Janssen Pharmaceutica Nv HIV-inhibiting pyrimidine derivatives
DE19851421A1 (en) * 1998-11-07 2000-05-11 Boehringer Ingelheim Pharma New pyrimidines, their production and use
KR100785360B1 (en) 1999-09-24 2007-12-18 얀센 파마슈티카 엔.브이. Antiviral composition
US6410726B1 (en) * 2000-01-12 2002-06-25 Tularik Inc. Arylsulfonic acid salts of pyrimidine-based antiviral
RU2003135424A (en) * 2001-05-14 2005-05-20 Бристол-Маерс Сквибб Фарма Компани (Us) SUBSTITUTED PYRAZINONES, PYRIDINES AND PYRIMIDINES AS LIGANDS OF CORTICOTROPINE RELAXING FACTOR
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
NZ537752A (en) 2002-07-29 2006-12-22 Rigel Pharmaceuticals Inc Use of 2,4-pyrimidinediamine compounds in the preparation of medicaments for treating autoimmune diseases
US20040242566A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
AU2004253967B2 (en) * 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
JP4886511B2 (en) 2003-07-30 2012-02-29 ライジェル ファーマシューティカルズ, インコーポレイテッド Method for treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
CA2535619A1 (en) 2003-08-13 2005-02-24 Takeda Pharmaceutical Company Limited 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
JP2007505121A (en) 2003-09-08 2007-03-08 武田薬品工業株式会社 Dipeptidyl peptidase inhibitor
GEP20094679B (en) 2004-03-15 2009-05-10 Takeda Pharmaceuticals Co Dipeptidyl peptidase inhibitors
DK1814878T3 (en) 2004-11-24 2012-05-07 Rigel Pharmaceuticals Inc SPIRO-2,4-PYRIMIDINE DIAMINE COMPOUNDS AND APPLICATIONS THEREOF
US7872124B2 (en) 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
KR101278397B1 (en) 2005-01-19 2013-06-25 리겔 파마슈티칼스, 인크. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
CA2604551A1 (en) * 2005-05-03 2007-03-08 Rigel Pharmaceuticals, Inc. Jak kinase inhibitors and their uses
JP5148483B2 (en) 2005-05-26 2013-02-20 テイボテク・フアーマシユーチカルズ Process for producing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl) aminobenzonitrile
ME02005B (en) 2005-09-14 2012-08-31 Takeda Pharmaceuticals Co Dipeptidyl peptidase inhibitors for treating diabetes
CN101360723A (en) 2005-09-16 2009-02-04 武田药品工业株式会社 Process for preparing pyrimidinedione derivatives
EP1993612A4 (en) * 2006-01-31 2010-05-05 Univ Yale COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
CL2008000467A1 (en) 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv COMPOUNDS DERIVED FROM 2-AMINOPIRIMIDINE, HISTAMINE RECEIVER MODULATORS H4; YOUR PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT A SELECTED INFLAMMATORY DISORDER OF ALEGIA, ASMA
US20080217501A1 (en) * 2007-02-14 2008-09-11 Chad Jensen Power a-frame
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
TWI468407B (en) * 2008-02-06 2015-01-11 Du Pont Mesoionic pesticides
WO2012135697A2 (en) * 2011-03-30 2012-10-04 H. Lee Moffitt Cancer Center & Research Institute Inc. Novel rho kinase inhibitors and methods of use
US10172856B2 (en) 2017-04-06 2019-01-08 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives as histamine H4 modulators
AU2018352695A1 (en) 2017-10-19 2020-05-28 Effector Therapeutics, Inc. Benzimidazole-indole inhibitors of Mnk1 and Mnk2

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB815833A (en) * 1956-09-26 1959-07-01 Boots Pure Drug Co Ltd Phenanthridine compounds
BE492034A (en) * 1948-11-05
US2784124A (en) * 1953-07-01 1957-03-05 Howard R Moore Method of coating ferrous metal surface and composition therefor
US2748124A (en) * 1954-05-06 1956-05-29 Searle & Co 1-(4-anilino-2-pyrimidino)-3-alkylureas
US2845425A (en) * 1956-10-04 1958-07-29 Lilly Co Eli Substituted aminopyrimidines
DE1241832B (en) * 1963-02-23 1967-06-08 Hoechst Ag Process for the preparation of pyrimidinium compounds
DE1445740A1 (en) * 1963-09-04 1968-11-28 Bayer Ag Process for the preparation of bispyrimidinium compounds
GB1229413A (en) * 1967-06-14 1971-04-21
IN142539B (en) * 1974-05-10 1977-07-23 Ciba Geigy India Ltd
US4339453A (en) * 1979-07-23 1982-07-13 Merck & Co., Inc. Antimicrobial aminopyrimidinium salts
GR80171B (en) * 1983-08-29 1985-01-02 Ciba Geigy Ag N-(2-nitrophenyl)-4-aminopyrimidine derivatives process for the preparation thereof and use
US4725600A (en) * 1984-07-13 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent
DE3717480A1 (en) * 1987-05-23 1988-12-01 Shell Agrar Gmbh & Co Kg Novel herbicidal and microbicidal 2,6-diaminopyrimidines
IL88507A (en) * 1987-12-03 1993-02-21 Smithkline Beckman Intercredit 2,4-diaminoquinazolines, process for their preparation and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
CA2014457C (en) 1999-09-28
US5223505A (en) 1993-06-29
GR900100304A (en) 1991-09-27
ES2064727T3 (en) 1995-02-01
ATE112561T1 (en) 1994-10-15
GB9007964D0 (en) 1990-06-06
GB2230527A (en) 1990-10-24
NO905519D0 (en) 1990-12-20
NO177054C (en) 1995-07-12
DK0422178T3 (en) 1994-12-19
YU79990A (en) 1991-10-31
AU635260B2 (en) 1993-03-18
PL165502B1 (en) 1994-12-30
CN1024793C (en) 1994-06-01
AU5435490A (en) 1990-11-16
PT93823A (en) 1990-11-20
DE69013112T2 (en) 1995-01-26
GR1000371B (en) 1992-06-30
MY105637A (en) 1994-11-30
WO1990012790A1 (en) 1990-11-01
CA2014457A1 (en) 1990-10-21
BG93508A (en) 1993-12-24
HU209586B (en) 1994-08-29
IE63502B1 (en) 1995-05-03
IL94062A0 (en) 1991-01-31
FI95377B (en) 1995-10-13
GB2230527B (en) 1993-05-05
HU903555D0 (en) 1991-05-28
HUT56080A (en) 1991-07-29
SI9010799A (en) 1995-08-31
NZ233292A (en) 1992-05-26
NO905519L (en) 1991-02-20
MW9090A1 (en) 1991-11-13
DE69013112D1 (en) 1994-11-10
IL94062A (en) 1995-11-27
EP0422178B1 (en) 1994-10-05
EP0422178A1 (en) 1991-04-17
PT93823B (en) 1996-09-30
JPH03505741A (en) 1991-12-12
RU2108329C1 (en) 1998-04-10
NO177054B (en) 1995-04-03
PL165917B1 (en) 1995-03-31
FI95377C (en) 1996-01-25
KR920700203A (en) 1992-02-19
JP2528218B2 (en) 1996-08-28
IE901258L (en) 1990-10-21
CN1047080A (en) 1990-11-21
HRP930793A2 (en) 1996-08-31

Similar Documents

Publication Publication Date Title
FI906307A0 (en) Process for the preparation of therapeutically active pyrimidine derivatives
DE3873612D1 (en) DITHIOACETAL COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
ATE102210T1 (en) 1H,3H,7-PYRROLO(1,2-C&gt;THIAZOLCARBONIC ACID REAMIDE DERIVATIVES, THEIR MANUFACTURE AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM.
FI911925A0 (en) AMINDERIVAT.
MY106091A (en) Heterocyclic compounds.
ATE48994T1 (en) BENZIMIDAZOLE DERIVATIVE, PROCESS FOR ITS PRODUCTION AND PHARMACEUTICAL COMPOSITION.
AU639154B2 (en) New imidazole compounds, a process for the preparation thereof, and pharmaceutical compositions containing them
JO1631B1 (en) Pyrimidine derivatives
ATE131480T1 (en) PYRIMIDOINDOLE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
FR2655042B1 (en) NOVEL SUBSTITUTED BENZOTHIAZOLINONES, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: ZENECA LIMITED

BB Publication of examined application
MM Patent lapsed

Owner name: ZENECA LIMITED